Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer - OncLive
6/5/2022 12:00:00 AM2 years 11 months ago
by Jordyn Sava
by Jordyn Sava
Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.
Treatment with larotrectinib (Vitrakvi) elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system (CNS) TRK fusion … [+4251 chars]
full article...